- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made).
25.—(1) The Medicines Act 1968 shall be amended as follows—
(a)in section 7 (general provisions as to dealing with medicinal products) omit paragraph (a) of subsection (6A)(1);
(b)in section 8 (provisions as to manufacture and wholesale dealing), omit paragraph (a) of subsection (4)(2);
(c)in section 130 (meaning of “medicinal product” and related expressions) in subsection (5), after paragraph (b), insert the following new paragraph—
“(ba) whole human blood and human blood components;”.
(d)In section 130, after subsection (5A) insert the following new subsection—
“(5B) For the purposes of this section, “human blood component” means any of the following constituents of human blood: red cells, white cells, platelets and plasma.”.
(2) The Medicines (Standard Provisions for Licenses and Certificates) Regulations 1971 shall be amended as follows—
(a)in regulation 2 (interpretation), after the definition of “BCG vaccine” insert the following definitions—
““blood” means whole human blood;
“blood component” means a therapeutic constituent of blood (red cells, white cells, platelets and plasma);”; and
(b)in Schedule 2 insert the following new paragraph—
“5C. The licence holder shall ensure that any blood or blood component imported into the United Kingdom and used by him as a starting material or raw material in the manufacture of a medicinal product, shall meet equivalent standards of quality and safety to those laid down in Commission Directive 2004/33/EC, implementing Directive 2003/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components.”.
(3) In the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994(3), in regulation 1 (citation, commencement and interpretation), in paragraph (2), in the definition of “the 2001 Directive”, after “as amended by” insert—
“Directive 2002/98/EC of the European Parliament and of the Council setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC,”.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: